首页> 外文期刊>Cancer Informatics >A Hypothesis-Directed Approach to the Targeted Development of a Multiplexed Proteomic Biomarker Assay for Cancer
【24h】

A Hypothesis-Directed Approach to the Targeted Development of a Multiplexed Proteomic Biomarker Assay for Cancer

机译:针对癌症的多重蛋白质组学生物标志物测定的目标发展的假设导向方法

获取原文
           

摘要

In recent years, hundreds of candidate protein biomarkers have been identified using discovery-based proteomics. Despite the large number of candidate biomarkers, few proteins advance to clinical validation. We propose a hypothesis-driven approach to identify candidate biomarkers, previously characterized in the literature, with the highest probability of clinical applicability. A ranking method, called the “hypothesis-directed biomarker ranking” (HDBR) system, was developed to score candidate biomarkers based on seven criteria deemed important in the selection of clinically useful biomarkers. To demonstrate its application, we applied the HDBR system to identify candidate biomarkers for the development of a diagnostic test for the early detection of colorectal cancer. One-hundred and fifty-one candidate biomarkers were identified from the literature and ranked based on the specified criteria. The top-ranked candidates represent a group of biomarkers whose further study and validation would be justified in order to expedite the development of biomarkers that could be used in a clinical setting.
机译:近年来,已经使用基于发现的蛋白质组学鉴定了数百种候选蛋白质生物标志物。尽管候选生物标志物很多,但很少有蛋白质推进临床验证。我们提出了一种假设驱动的方法来识别以前在文献中表征的候选生物标志物,具有最高的临床适用性可能性。一种称为“假设导向的生物标志物排名”(HDBR)系统的排名方法,以基于在选择临床上有用的生物标志物中认为重要的七个标准来得分候选生物标志物。为了证明其应用,我们应用了HDBR系统以识别候选生物标志物,以便在早期检测结直肠癌的诊断测试。从文献中鉴定了一百五十次候选生物标志物,并根据指定的标准排列。排名排名第一的候选人代表一组生物标志物,其进一步研究和验证是合理的,以便加快可以在临床环境中使用的生物标志物的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号